

Abiratas 500mg Tablet
₹30,193.00 Original price was: ₹30,193.00.₹14,000.00Current price is: ₹14,000.00.
Prescription Required
Salt : Abiraterone Acetate
Manufacturer : Intas Pharmaceuticals Ltd
Packing : 60 tablets in 1 bottle
PRODUCT INTRODUCTION
Abiratas 500mg Tablet is a specialized medication that plays a critical role in the field of oncology, particularly in the treatment of prostate cancer. The active ingredient in Abiratas is Abiraterone Acetate, a potent inhibitor of the enzyme CYP17A1, which is crucial in the biosynthesis of androgens (male hormones). These hormones can promote the growth of prostate cancer cells. Abiraterone works by lowering androgen production, thus helping to control the progression of the disease.
Manufactured by reputable pharmaceutical companies, Abiratas 500mg comes in tablet form and is intended for oral administration. It is generally prescribed as part of a combination therapy, often alongside prednisone or other corticosteroids, to manage hormone levels effectively and mitigate potential side effects related to adrenal insufficiency due to decreased androgen levels.
USES OF Abiratas 500mg Tablet
Abiratas 500mg Tablet is primarily used in the treatment of metastatic castration-resistant prostate cancer (mCRPC), a stage of cancer where the disease progresses despite low levels of testosterone typically achieved by medical or surgical treatments. The drug is also indicated for high-risk metastatic castration-sensitive prostate cancer (mCSPC), providing an option to delay the progression of cancer in patients who are newly diagnosed or those previously treated with androgen deprivation therapy.
BENEFITS OF Abiratas 500mg Tablet
The introduction of Abiratas 500mg in cancer treatment has been marked by significant benefits:
- Extended Survival: Clinical trials have consistently shown that Abiratas 500mg extends overall survival rates in patients with mCRPC. The extension of survival is significant compared to other treatments, offering patients more valuable time and improved quality of life.
- Progression Delay: For patients with metastatic castration-sensitive disease, Abiratas has been effective in delaying the progression of prostate cancer. This can mean fewer symptoms and a slower decline in health, which can be crucial for maintaining life quality.
- Reduction in Pain and Other Symptoms: By controlling the growth and spread of cancer cells, Abiratas helps in reducing pain and other debilitating symptoms associated with advanced prostate cancer, thereby improving patient comfort and daily functioning.
- Hormonal Control: Abiratas effectively reduces the levels of androgens, which are known to fuel the growth of prostate cancer cells. This hormonal control is vital for managing prostate cancer long-term, particularly in patients who no longer respond to traditional hormonal therapies.
SIDE EFFECTS OF Abiratas 500mg Tablet
While Abiratas 500mg provides substantial benefits in treating prostate cancer, it also comes with a range of potential side effects that patients should be aware of. Common side effects include:
- Hypertension: Due to its mechanism of action, Abiratas may increase blood pressure. Regular monitoring and management with antihypertensive medications may be necessary.
- Fluid Retention/Edema: Patients may experience swelling and fluid retention, necessitating the use of diuretics or other supportive treatments.
- Hypokalemia: Low levels of potassium in the blood can occur, which might require dietary adjustments or supplementation.
- Liver Function Abnormalities: Elevations in liver enzymes may occur, indicating liver stress or damage. Liver function tests should be regularly performed to monitor the organ’s response to the treatment.
- Fatigue and Joint Pain: These are common but generally manageable with pain relievers and lifestyle modifications.
- Hot Flashes and Urinary Tract Symptoms: These are often due to the reduced androgen levels and can be addressed with supportive care.
References
-
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 4-5.
Disclaimer
Singhla Medicos’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Singhla Medicos. Our mission is to support, not replace, the doctor-patient relationship.
Shipping Policy
We ship across India. Note – this is subject to change as per Company Wishes. Packages will be shipped in 24 working hours. we are closed on Sundays and will reach you in the next 2-4 days post shipping. We give the estimated time of delivery on the shipping page. However, these are indicative and depend on our shipping partner.
Delivery
The delivery times are subject to location, distance, and our logistics partners. We are not liable for any delays in delivery by the courier company/postal authorities but will help you track down a package through our partner courier services.
Your purchases may reach you from various locations in more than one package. But rest assured, you will be charged one delivery fee for the entire order. As soon as your package ships, we will email you your package tracking information.
We are bound in coverage by their reach even though we use some of India’s largest logistics companies for shipping. In case your address is in a location not served by them we would contact you to find an alternative solution to make your products reach you.
Related products
Arpimune-O 50mg Capsule

Cresp 40 Injection


Denub 60mg Injection


Fragmin 5000IU Injection

Guficandin 50mg Injection


Lonopin 40mg Injection

Rebopag 25mg Tablet

Reviews
There are no reviews yet.